VENUS REMEDIES
Back to Balance Sheet
|
VENUS REMEDIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹60 Cr | ₹58 Cr | ₹46 Cr | ₹58 Cr | ₹96 Cr |
What is the latest Total Non-Current Liabilities ratio of VENUS REMEDIES ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹60 Cr |
Mar2023 | ₹58 Cr |
Mar2022 | ₹46 Cr |
Mar2021 | ₹58 Cr |
Mar2020 | ₹96 Cr |
How is Total Non-Current Liabilities of VENUS REMEDIES Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹60 Cr | 2.89 | |
Mar2023 | ₹58 Cr | 26.60 | |
Mar2022 | ₹46 Cr | -20.94 | |
Mar2021 | ₹58 Cr | -39.34 | |
Mar2020 | ₹96 Cr | - |
Compare Total Non-Current Liabilities of peers of VENUS REMEDIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
VENUS REMEDIES | ₹391.3 Cr | -3.2% | -10.4% | -12.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹431,352.0 Cr | 1.7% | -4.7% | 48.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,265.0 Cr | 4.4% | 3.1% | 66% | Stock Analytics | |
CIPLA | ₹120,035.0 Cr | -0.9% | -1.7% | 17.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,286.0 Cr | -1% | -8.9% | 6.5% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,461.4 Cr | -1% | -4% | 48.4% | Stock Analytics |
VENUS REMEDIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
VENUS REMEDIES | -3.2% |
-10.4% |
-12.7% |
SENSEX | 1.8% |
-2.5% |
19.9% |
You may also like the below Video Courses